Biotech firm Repligen beats Q3 revenue estimates, raises guidance

Repligen

28/10/2025 11:40

Overview

Repligen Q3 revenue grows 22% yr/yr, beating analyst expectations

Adjusted EPS for Q3 beats consensus, reflecting strong operational performance

Company raises full-year revenue guidance to $729-$737 mln, indicating confidence in growth

Outlook

Repligen raises full-year revenue guidance to $729 mln - $737 mln

Company expects full-year adjusted EPS of $1.65 - $1.68

Repligen forecasts full-year adjusted gross margin of 52% - 53%

Result Drivers

BROAD-BASED GROWTH - All franchises and geographies posted double-digit revenue and order growth, with consumables and capital equipment revenues growing over 20%

SOLOVPE PLUS LAUNCH - Record quarter for Process Analytics equipment placements following the launch of SoloVPE PLUS

NOVASIGN PARTNERSHIP - Strategic partnership with Novasign to integrate digital twin capabilities into filtration systems

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Beat
$189 mln
$181.10 mln (20 Analysts)
Q3 Adjusted EPS
Beat
$0.46
$0.41 (17 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Repligen Corp is $180.00, about 10.5% above its October 27 closing price of $161.10

The stock recently traded at 77 times the next 12-month earnings vs. a P/E of 65 three months ago

Press Release: ID:nGNX4lTCks

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)